touchPANEL DISCUSSION for touchNEUROLOGY
Listen to a panel of leading multiple sclerosis (MS) experts discuss their perspectives on the benefits of disease-modifying therapies (DMTs) in MS, and current approaches to treatment sequencing.
The experts
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchneurology.com/cme/treatment-sequencing-in-ms-the-benefits-of-dmts/
Fulfilling the potential of HER2-targeting in colorectal cancer
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies - Modules 1 & 2
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
Shaping ART around individual needs: Maximizing adherence and quality of life
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
Key considerations for treatment selection and sequencing in patients with RRMM Lessons from real-life clinical practice
Individualizing long-term treatment and care in active MS
MDT perspectives on approaches for the use of immune checkpoint inhibitor therapy in patients with solid tumours
MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types
MDT perspectives on strategies for identifying and monitoring immune-related adverse events
MDT perspectives on indications for immune checkpoint inhibitors in patients with solid tumours
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in the Middle East
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
The Psychic Elephant Radio Podcast
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain